MDT

96.13

-0.07%↓

A

143.79

-2.29%↓

VEEV

227.66

-3.26%↓

HQY

83.45

-2.26%↓

PHR.US

16.38

-3.99%↓

MDT

96.13

-0.07%↓

A

143.79

-2.29%↓

VEEV

227.66

-3.26%↓

HQY

83.45

-2.26%↓

PHR.US

16.38

-3.99%↓

MDT

96.13

-0.07%↓

A

143.79

-2.29%↓

VEEV

227.66

-3.26%↓

HQY

83.45

-2.26%↓

PHR.US

16.38

-3.99%↓

MDT

96.13

-0.07%↓

A

143.79

-2.29%↓

VEEV

227.66

-3.26%↓

HQY

83.45

-2.26%↓

PHR.US

16.38

-3.99%↓

MDT

96.13

-0.07%↓

A

143.79

-2.29%↓

VEEV

227.66

-3.26%↓

HQY

83.45

-2.26%↓

PHR.US

16.38

-3.99%↓

Search

Certara Inc

Open

SectorHealthcare

9.2 -1.08

Overview

Share price change

24h

Current

Min

9.13

Max

9.41

Key metrics

By Trading Economics

Income

3.5M

1.5M

Sales

46K

105M

P/E

Sector Avg

129.143

87.826

Profit margin

1.458

Employees

1,487

EBITDA

-6.5M

23M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+25.23% upside

Dividends

By Dow Jones

Next Earnings

25 lut 2026

Market Stats

By TradingEconomics

Market Cap

-439M

1.4B

Previous open

10.28

Previous close

9.2

News Sentiment

By Acuity

50%

50%

173 / 370 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

Certara Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

12 sty 2026, 23:54 UTC

Market Talk

CBA Could Underperform Again in 2026 -- Market Talk

12 sty 2026, 23:48 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

12 sty 2026, 23:48 UTC

Market Talk

Nikkei May Rise on Weaker Yen -- Market Talk

12 sty 2026, 23:43 UTC

Market Talk

Gold Edges Lower on Likely Technical Correction -- Market Talk

12 sty 2026, 23:18 UTC

Acquisitions, Mergers, Takeovers

Paramount Sues Warner Bros., Plans Proxy Fight. The Ellisons Aren't Giving Up. -- Barrons.com

12 sty 2026, 21:56 UTC

Market Talk

Light & Wonder Gets Positive Outcome From Lawsuit -- Market Talk

12 sty 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

12 sty 2026, 21:50 UTC

Market Talk

Health Care Roundup: Market Talk

12 sty 2026, 21:50 UTC

Market Talk
Earnings

Auto & Transport Roundup: Market Talk

12 sty 2026, 21:18 UTC

Market Talk

Global Equities Roundup: Market Talk

12 sty 2026, 21:18 UTC

Market Talk

Pfizer CEO Sees Large Cash Market for Obesity Drugs -- Market Talk

12 sty 2026, 20:54 UTC

Earnings

Gap, Fortinet, and More Stocks That Usually Outperform After Earnings -- Barrons.com

12 sty 2026, 20:48 UTC

Market Talk

Oil Futures Settle Higher in Choppy Trade -- Market Talk

12 sty 2026, 20:33 UTC

Market Talk

U.S. Natural Gas Jumps on Colder Weather Outlook -- Market Talk

12 sty 2026, 20:18 UTC

Acquisitions, Mergers, Takeovers

Credit Agricole Sees Banco BPM Stake Helping 2025 Net by EUR200M >ACA.FR

12 sty 2026, 20:18 UTC

Acquisitions, Mergers, Takeovers

Credit Agricole: European Central Bank Approves Crossing of 20% Threshold in Share Capital of Banco BPM

12 sty 2026, 19:39 UTC

Market Talk

J&J CEO: Trump Pact Allows Company to Focus on Core Operations -- Market Talk

12 sty 2026, 19:36 UTC

Market Talk

Gold and Silver Set New Records on Fed Probe -- Market Talk

12 sty 2026, 19:36 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

12 sty 2026, 19:33 UTC

Market Talk

Venezuela's 'Proven' Oil Reserves Raises Questions -- Market Talk

12 sty 2026, 19:24 UTC

Acquisitions, Mergers, Takeovers

Dynavax: 'Party A' CEO Sent a Non-Binding $15/Shr Proposal on Dec. 23

12 sty 2026, 19:22 UTC

Acquisitions, Mergers, Takeovers

Dynavax Files Tender Offer Recommendation Statement Related to Sanofi Deal, Mentions Talks With 'Party A'

12 sty 2026, 18:21 UTC

Acquisitions, Mergers, Takeovers

Paramount Plans Proxy Fight to Push Hostile Warner Bid -- 2nd Update

12 sty 2026, 18:20 UTC

Acquisitions, Mergers, Takeovers

This French Biotech Stock Surged 1,700% in 2025. Eli Lilly Is Taking an Interest. -- Barrons.com

12 sty 2026, 18:19 UTC

Market Talk

Modest Canadian Economic Impact Seen from Venezuela Changes -- Market Talk

12 sty 2026, 18:16 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Comcast Could Unlock Value With a Spinoff of NBCUniversal Assets, Analysts Say -- Market Talk

12 sty 2026, 18:09 UTC

Market Talk

Global Equities Roundup: Market Talk

12 sty 2026, 18:09 UTC

Market Talk

Baidu's Outlook Bodes Well For Shares -- Market Talk

12 sty 2026, 18:01 UTC

Acquisitions, Mergers, Takeovers

QXO Is Raising Another $1.8 Billion for Its M&A War Chest -- Barrons.com

12 sty 2026, 18:00 UTC

Market Talk

Canada's 'Breakeven' Employment Recalibrating -- Market Talk

Peer Comparison

Price change

Certara Inc Forecast

Price Target

By TipRanks

25.23% upside

12 Months Forecast

Average 12.11 USD  25.23%

High 16 USD

Low 9 USD

Based on 11 Wall Street analysts offering 12 month price targets forCertara Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

11 ratings

7

Buy

4

Hold

0

Sell

Technical Score

By Trading Central

11.27 / 12.79Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Very Strong Bullish Evidence

Long Term

Strong Bullish Evidence

Sentiment

By Acuity

173 / 370 Ranking in Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Certara Inc

Certara, Inc., together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics. The company provides Simcyp Simulator, a mechanistic biosimulation platform mechanistic biosimulation investigational new drug and translational stages; Simcyp Biopharmaceutics, used to identify and refine drug formulations; and Simcyp Secondary Intelligence which integrates toxicology with quantitative analysis of networks of molecular and functional biological changes to identify drug toxicity and adverse drug reactions. In addition, it offers Phoenix WinNonlin, a platform for non-compartmental analysis, pharmacokinetic/pharmacodynamic, and toxicokinetic; phoenix hosted, that provides a secured and validated certara amazon web services workspace; Phoenix NLME, a population modeling and simulation software for nonlinear mixed effects models; and pirana modeling workbench. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange, used to define data standards and specifications; and Metadata Repository, to enable study design using controlled and standardized data. It serves life sciences companies, biopharmaceutical companies, research organizations, academic institutions, and global regulators, as well as animal health, crop science, bio science, medical devices, and public sector industries. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.
help-icon Live chat